The study for surgical outcome of trabeculectomy for neovascular glaucomatous patients who received bevacizumab treatment before the surgery.

The study for surgical outcome of trabeculectomy for neovascular glaucomatous patients who received bevacizumab treatment before the surgery. - Surgical outcome in neovascular glaucomatous patients with bevacizumab before trabeculectomy.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001136

Enrollment

Registered

2008-05-05

Start date

2008-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with neovascular glaucoma

Interventions

Patients are treated with an intravitreal injection of 1.25 mg bevacizumab (avastin) between 2 and 5 days before trabeculectomy, then treated with trabeculectomy. Patients are treated with trabeculec

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with neovascular glaucoma. Intraocular pressure levels of 22 mmHg or higher.

Exclusion criteria

Exclusion criteria: Patients who have been previously treated with trabeculectomy. Patients who had been treated with bevacizumab within recent 2 months.

Design outcomes

Primary

Measure	Time frame
Intraocular pressure levels after trabeculectomy	—

Secondary

Measure	Time frame
Bleb formation Inflammatory reaction in anterior chamber.	—

Countries

Japan

Contacts

Public ContactMasaru Inatani

Kumamoto University Graduate School of Medical Sciences Department of Ophthalmology and Visual Science

inatani@u-fukui.ac.jp0776-61-8403

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026